CA3206520A1 - Inhibitors of cgas activity as therapeutic agents - Google Patents

Inhibitors of cgas activity as therapeutic agents Download PDF

Info

Publication number
CA3206520A1
CA3206520A1 CA3206520A CA3206520A CA3206520A1 CA 3206520 A1 CA3206520 A1 CA 3206520A1 CA 3206520 A CA3206520 A CA 3206520A CA 3206520 A CA3206520 A CA 3206520A CA 3206520 A1 CA3206520 A1 CA 3206520A1
Authority
CA
Canada
Prior art keywords
alkyl
carboxylic acid
pyrrolidine
pyrimidin
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3206520A
Other languages
English (en)
French (fr)
Inventor
Robert G. Lowery
Meera Kumar
Matthew Boxer
David Maloney
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BellBrook Labs LLC
Original Assignee
BellBrook Labs LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BellBrook Labs LLC filed Critical BellBrook Labs LLC
Publication of CA3206520A1 publication Critical patent/CA3206520A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA3206520A 2021-02-11 2022-02-11 Inhibitors of cgas activity as therapeutic agents Pending CA3206520A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163148201P 2021-02-11 2021-02-11
US63/148,201 2021-02-11
PCT/US2022/016073 WO2022174012A1 (en) 2021-02-11 2022-02-11 INHIBITORS OF cGAS ACTIVITY AS THERAPEUTIC AGENTS

Publications (1)

Publication Number Publication Date
CA3206520A1 true CA3206520A1 (en) 2022-08-18

Family

ID=82837325

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3206520A Pending CA3206520A1 (en) 2021-02-11 2022-02-11 Inhibitors of cgas activity as therapeutic agents

Country Status (8)

Country Link
US (1) US20240174684A1 (https=)
EP (1) EP4291188A4 (https=)
JP (1) JP2024506904A (https=)
KR (1) KR20230144550A (https=)
CN (1) CN116997339A (https=)
AU (1) AU2022218787A1 (https=)
CA (1) CA3206520A1 (https=)
WO (1) WO2022174012A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119119063A (zh) 2021-05-12 2024-12-13 勃林格殷格翰国际有限公司 作为cGAS抑制剂的具有N-连接环状取代基的吡啶衍生物
WO2022238335A1 (en) * 2021-05-12 2022-11-17 Boehringer Ingelheim International Gmbh Pyridine derivatives with c-linked cyclic substituents as cgas inhibitors
JP2025528113A (ja) * 2022-08-10 2025-08-26 ベルブルック ラボズ，エルエルシー 治療剤としてのｃＧＡＳ活性の阻害剤
KR20250103719A (ko) * 2022-11-09 2025-07-07 베링거 인겔하임 인터내셔날 게엠베하 cGAS 억제제로서의 사이클릭 벤즈이미다졸 유도체
AU2023376006A1 (en) * 2022-11-09 2025-03-13 Boehringer Ingelheim International Gmbh Cyclic pyridine derivatives as cgas inhibitors
WO2025233174A1 (en) 2024-05-08 2025-11-13 Boehringer Ingelheim International Gmbh Benzimidazole derivatives as cgas inhibitors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20090028819A (ko) * 2006-07-11 2009-03-19 얀센 파마슈티카 엔.브이. 히스타민 ｈ４ 수용체의 벤조푸로- 및 벤조티에노피리미딘 조절제
WO2008074445A1 (en) * 2006-12-18 2008-06-26 Ucb Pharma, S.A. Novel tricyclic and heterotricyclic derivatives, processes for preparing them, pharmaceutical compositions thereof
WO2013115167A1 (ja) * 2012-01-31 2013-08-08 エーザイ・アール・アンド・ディー・マネジメント株式会社 アムバチニブ誘導体
EP3565810A1 (en) * 2017-01-03 2019-11-13 ViiV Healthcare UK (No.5) Limited Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication
CA3125625A1 (en) * 2019-01-04 2020-07-09 Bellbrook Labs, Llc Inhibitors of cgas activity as therapeutic agents

Also Published As

Publication number Publication date
WO2022174012A1 (en) 2022-08-18
JP2024506904A (ja) 2024-02-15
KR20230144550A (ko) 2023-10-16
EP4291188A1 (en) 2023-12-20
US20240174684A1 (en) 2024-05-30
AU2022218787A1 (en) 2023-08-17
EP4291188A4 (en) 2025-01-08
CN116997339A (zh) 2023-11-03

Similar Documents

Publication Publication Date Title
CA3206520A1 (en) Inhibitors of cgas activity as therapeutic agents
AU2021345111B2 (en) Indole derivatives as Ras inhibitors in the treatment of cancer
AU2020379734B2 (en) Ras inhibitors
ES2866152T3 (es) Derivados de tirosina amida como inhibidores de la Rho-quinasa
US11337970B2 (en) Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
CN107614499B (zh) 吡啶并［3，4-d］嘧啶衍生物及其药学上可允许的盐
CA3160142A1 (en) Ras inhibitors
IL285215B2 (en) Immunomodulators, compositions and methods thereof
CA3125625A1 (en) Inhibitors of cgas activity as therapeutic agents
TW202321252A (zh) 新穎螺環吡咯啶衍生的抗病毒劑
CA2679807A1 (en) Piperidine derivatives and methods of use thereof
US12427146B2 (en) C-terminal SRC kinase inhibitors
US20220370431A1 (en) C-myc mrna translation modulators and uses thereof in the treatment of cancer
KR20230113289A (ko) P2x3 억제제로서 프탈라진 유도체
EP4263546B1 (en) Dihydrofuropyridine derivatives as rho- kinase inhibitors
CA3212863A1 (en) Indoline derivatives as ddr1 and ddr2 inhibitors
CN115894376B (zh) 一种芳香族酰胺类化合物、药物组合物及其用途
WO2024035622A1 (en) INHIBITORS OF cGAS ACTIVITY AS THERAPEUTIC AGENTS
US12404283B2 (en) c-MYC mRNA translation modulators and uses thereof in the treatment of cancer
WO2025255442A1 (en) Trim21-targeted compounds and uses thereof
CN116600810A (zh) 作为rho-激酶抑制剂的二氢呋喃并吡啶衍生物
EA047132B1 (ru) Антивирусные гетероциклические соединения
BR112020013759A2 (pt) triazóis substituídos por heterociclilamino como moduladores de proteína cinase associada a rho

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250127

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250127

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250127

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260325